Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Sep 14;12(9):e0184094.
doi: 10.1371/journal.pone.0184094. eCollection 2017.

Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer

Marilesia Ferreira de Souza  1 , Hellen Kuasne  2 , Mateus de Camargo Barros-Filho  2 , Heloísa Lizotti Cilião  1 , Fabio Albuquerque Marchi  2 , Paulo Emilio Fuganti  3 , Alexandre Rossi Paschoal  4 , Silvia Regina Rogatto  2   5 , Ilce Mara de Syllos Cólus  1
Affiliations
Clinical Trial

Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer

Marilesia Ferreira de Souza et al. PLoS One. .

Abstract

Circulating nucleic acids are found in free form in body fluids and may serve as minimally invasive tools for cancer diagnosis and prognosis. Only a few studies have investigated the potential application of circulating mRNAs and microRNAs (miRNAs) in prostate cancer (PCa). The Cancer Genome Atlas (TCGA) database was used for an in silico analysis to identify circulating mRNA and miRNA as potential markers of PCa. A total of 2,267 genes and 49 miRNAs were differentially expressed between normal and tumor samples. The prediction analyses of target genes and integrative analysis of mRNA and miRNA expression revealed eleven genes and eight miRNAs which were validated by RT-qPCR in plasma samples from 102 untreated PCa patients and 50 cancer-free individuals. Two genes, OR51E2 and SIM2, and two miRNAs, miR-200c and miR-200b, showed significant association with PCa. Expression levels of these transcripts distinguished PCa patients from controls (67% sensitivity and 75% specificity). PCa patients and controls with prostate-specific antigen (PSA) ≤ 4.0 ng/mL were discriminated based on OR51E2 and SIM2 expression levels. The miR-200c expression showed association with Gleason score and miR-200b, with bone metastasis, bilateral tumor, and PSA > 10.0 ng/mL. The combination of circulating mRNA and miRNA was useful for the diagnosis and prognosis of PCa.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Heatmap showing gene and miRNA differential expression in tumor tissue samples (1: purple) compared with surrounding normal tissues (2: orange) from TCGA data.
a Global gene expression analysis revealed 2,267 differentially expressed genes (P ≤ 0.001 and FDR ≤ 0.001); b miRNA expression analysis revealed 49 miRNAs differentially expressed (P ≤ 0.001 and FDR ≤ 0.001). Each line in the left axis represents a gene/miRNA. Columns represent each sample.
Fig 2
Fig 2. Flowchart of the analyses to define candidate genes.
*Gene selected from Pubmed database.
Fig 3
Fig 3. Differential expression of circulating mRNAs and miRNAs in plasma samples from patients with PCa and CTR and their respective ROC curves.
a Expression analysis of patients versus controls. b Differential expression of SIM2 and OR51E2 genes in plasma samples from patients versus controls, both with PSA level ≤ 4.0 ng/mL and their respective ROC curves. c ROC curve referring to the score developed from the following transcripts: miR-200c, miR-200b, OR51E2, and SIM2 genes; sensitivity of 67%, specificity of 75%. ROC = receiver operating characteristic, PCa = prostate cancer, CTR = controls subjects, PSA = prostate-specific antigen, AUC = area under the curve. *Statistically significant difference (Student’s t-test P < 0.05).
Fig 4
Fig 4. Comparison between circulating miR-200b expression levels and clinic-pathological features.
The superior line represents the miR200b expression according to the: a. presence or absence of metastasis; b. unilateral or bilateral tumors; c. Low or high PSA levels; and, d. Gleason score ≤ 6 or ≥ 7. e-h. The ROC (Receiver Operating Characteristic) curve analysis for each histopathological feature. PCa = prostate cancer; mPCa = metastatic prostate cancer; AUC = area under the curve. *Statistically significant (Student’s t-test P < 0.05).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer Statistics, 2012. CA a cancer J Clin. 2015;65(2): 87–108. - PubMed
    1. Instituto Nacional de Cancer José Alencar Gomes da Silva. INCA—Instituto Nacional de Câncer—Estimativa 2016. Ministério da Saúde Instituto Nacional de Cancer José Alencar Gomes da Silva. 2016. 124 p.
    1. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al. Combining Urinary Detection of TMPRSS2:ERG and PCA3 with Serum PSA to Predict Diagnosis of Prostate Cancer. Urol Oncol. 2013;31(5): 566–71. doi: 10.1016/j.urolonc.2011.04.001 - DOI - PMC - PubMed
    1. Strope SA, Andriole GL. Prostate cancer screening: current status and future perspectives. Nat Rev Urol. 2010;7(9): 487–93. doi: 10.1038/nrurol.2010.120 - DOI - PubMed
    1. Klotz L. Active surveillance for prostate cancer: Overview and update. Curr Treat Options Oncol. 2013;14(1): 97–108. doi: 10.1007/s11864-012-0221-5 - DOI - PubMed

MeSH terms

Grants and funding

This study was supported by grants from the Araucaria Foundation of Support for the Scientific and Technological of Paraná (185/2014), National Institute of Science and Technology in Oncogenomics (Sao Paulo Research Foundation FAPESP 2008/57887-9 and Brazilian National Council for Scientific and Technological Development CNPq 573589/08-9), Coordination for the Improvement of Higher Education Personnel Brazil (CAPES), Brazil and Vejle Hospital, Institute of Regional Health Research, Vejle, Denmark (K16-04V). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.